S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69

VBI Vaccines Stock Forecast, Price & News

-0.09 (-4.92%)
(As of 01/21/2022 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
3.56 million shs
Average Volume
2.66 million shs
Market Capitalization
$447.71 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive VBIV News and Ratings via Email

Sign-up to receive the latest news and ratings for VBI Vaccines and its competitors with MarketBeat's FREE daily newsletter.

VBI Vaccines logo

About VBI Vaccines

VBI Vaccines, Inc. is a biopharmaceutical company, which engages in the development of infectious disease and immuno-oncology vaccines. The firm focuses on the prevention and treatment of hepatitis B through its product pipeline, the Sci-B-Vac and VBI-2601. It also develops enveloped virus-like particle (eVLP) platform technology, which allows the development of eVLP vaccines that closely mimic the target virus to elicit a potent immune response. The company was founded on April 9, 1965 and is headquartered in Cambridge, MA.


VBI Vaccines Inc. (NASDAQ:VBIV) Short Interest Update
January 20, 2022 |  americanbankingnews.com
VBI Vaccines (NASDAQ:VBIV) Shares Down 3.8%
January 12, 2022 |  americanbankingnews.com
VBI Vaccines (NASDAQ:VBIV) Sets New 52-Week Low at $2.01
January 10, 2022 |  americanbankingnews.com
VBIV Jan 2022 4.500 call
December 16, 2021 |  finance.yahoo.com
FDA Approves VBI Vaccines' 3-Antigen Hepatitis B Vaccine
December 1, 2021 |  markets.businessinsider.com
See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$1.06 million
Book Value
$0.70 per share


Net Income
$-46.23 million
Net Margins
Pretax Margin




Free Float
Market Cap
$447.71 million

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Overall MarketRank

2.20 out of 5 stars

Medical Sector

402nd out of 1,419 stocks

Pharmaceutical Preparations Industry

186th out of 685 stocks

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.0 5 -4 -3 -2 -1 -

VBI Vaccines (NASDAQ:VBIV) Frequently Asked Questions

Is VBI Vaccines a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for VBI Vaccines in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" VBI Vaccines stock.
View analyst ratings for VBI Vaccines
or view top-rated stocks.

How has VBI Vaccines' stock price been impacted by Coronavirus?

VBI Vaccines' stock was trading at $0.9171 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, VBIV stock has increased by 89.7% and is now trading at $1.74.
View which stocks have been most impacted by COVID-19

Are investors shorting VBI Vaccines?

VBI Vaccines saw a decline in short interest in the month of December. As of December 31st, there was short interest totaling 15,190,000 shares, a decline of 19.4% from the December 15th total of 18,840,000 shares. Based on an average daily trading volume, of 3,380,400 shares, the days-to-cover ratio is currently 4.5 days.
View VBI Vaccines' Short Interest

When is VBI Vaccines' next earnings date?

VBI Vaccines is scheduled to release its next quarterly earnings announcement on Tuesday, March 1st 2022.
View our earnings forecast for VBI Vaccines

How were VBI Vaccines' earnings last quarter?

VBI Vaccines Inc. (NASDAQ:VBIV) issued its quarterly earnings data on Monday, November, 8th. The biopharmaceutical company reported ($0.06) earnings per share for the quarter, topping analysts' consensus estimates of ($0.07) by $0.01. The biopharmaceutical company earned $0.11 million during the quarter, compared to analysts' expectations of $0.26 million. VBI Vaccines had a negative trailing twelve-month return on equity of 39.02% and a negative net margin of 9,290.20%.
View VBI Vaccines' earnings history

What price target have analysts set for VBIV?

2 brokerages have issued 1-year price objectives for VBI Vaccines' shares. Their forecasts range from $6.00 to $6.00. On average, they expect VBI Vaccines' share price to reach $6.00 in the next year. This suggests a possible upside of 244.8% from the stock's current price.
View analysts' price targets for VBI Vaccines
or view top-rated stocks among Wall Street analysts.

Who are VBI Vaccines' key executives?

VBI Vaccines' management team includes the following people:
  • Jeff Baxter, President, Chief Executive Officer & Director
  • Christopher McNulty, CFO, Director & Head-Business Development
  • Francisco Diaz-Mitoma, Chief Medical Officer
  • David Evander Anderson, Chief Scientific Officer
  • T. Adam Buckley, Vice President-Business Development

What other stocks do shareholders of VBI Vaccines own?

Based on aggregate information from My MarketBeat watchlists, some companies that other VBI Vaccines investors own include BMO Capital Markets (), Stifel Nicolaus (), Wunderlich (), Standpoint Research (), Duncan Williams (), Soleil Securities (), Sterne Agee CRT (), Robert W. Baird (), Wellington Shields () and Macquarie ().

What is VBI Vaccines' stock symbol?

VBI Vaccines trades on the NASDAQ under the ticker symbol "VBIV."

Who are VBI Vaccines' major shareholders?

VBI Vaccines' stock is owned by many different retail and institutional investors. Top institutional investors include Newbridge Financial Services Group Inc. (0.07%), FNY Investment Advisers LLC (0.01%), Wealth Alliance Advisory Group LLC (0.00%) and Cutler Group LP (0.00%). Company insiders that own VBI Vaccines stock include Life Sciences Maste Perceptive, Nell Beattie and Perceptive Advisors Llc.
View institutional ownership trends for VBI Vaccines

Which institutional investors are selling VBI Vaccines stock?

VBIV stock was sold by a variety of institutional investors in the last quarter, including FNY Investment Advisers LLC, and Cutler Group LP. Company insiders that have sold VBI Vaccines company stock in the last year include Life Sciences Maste Perceptive, and Perceptive Advisors Llc.
View insider buying and selling activity for VBI Vaccines
or view top insider-selling stocks.

Which institutional investors are buying VBI Vaccines stock?

VBIV stock was purchased by a variety of institutional investors in the last quarter, including Newbridge Financial Services Group Inc., and Wealth Alliance Advisory Group LLC. Company insiders that have bought VBI Vaccines stock in the last two years include Life Sciences Maste Perceptive, and Nell Beattie.
View insider buying and selling activity for VBI Vaccines
or or view top insider-buying stocks.

How do I buy shares of VBI Vaccines?

Shares of VBIV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is VBI Vaccines' stock price today?

One share of VBIV stock can currently be purchased for approximately $1.74.

How much money does VBI Vaccines make?

VBI Vaccines has a market capitalization of $447.71 million and generates $1.06 million in revenue each year. The biopharmaceutical company earns $-46.23 million in net income (profit) each year or ($0.26) on an earnings per share basis.

How many employees does VBI Vaccines have?

VBI Vaccines employs 130 workers across the globe.

What is VBI Vaccines' official website?

The official website for VBI Vaccines is www.vbivaccines.com.

Where are VBI Vaccines' headquarters?

VBI Vaccines is headquartered at 222 Third Street Suite 2241, Cambridge MA, 02142.

How can I contact VBI Vaccines?

VBI Vaccines' mailing address is 222 Third Street Suite 2241, Cambridge MA, 02142. The biopharmaceutical company can be reached via phone at (617) 830-3031 or via email at [email protected].

This page was last updated on 1/23/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.